Insight

Alessandro Di Federico: EFS in patients with resectable NSCLC treated with neoadjuvant Chemo-IO

Alessandro Di Federico/X

Nov 3, 2024, 16:27

Alessandro Di Federico: EFS in patients with resectable NSCLC treated with neoadjuvant Chemo-IO

Alessandro Di Federico, Medical Oncologist and Ph.D. student at the University of Bologna, shared a post on X about a recent paper by Daniele Marinelli et al. published in the Journal of Thoracic Oncology:

“Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis”

Authors: Daniele Marinelli, Antonio Nuccio, Alessandro Di Federico, Giuseppe Viscard, Filippo Gallina et al.

“Fully published in Journal of Thoracic Oncology our individual patient data meta-analysis on EFS in patients with resectable NSCLC treated with neoadjuvant Chemo-IO. An effort led by Daniele Marinelli, Antonio Nuccio, Filippo Gallina on behalf of a young Italian multidisciplinary oncology group.

We tried to answer 2 main questions: – how strong is the association between pCR, MPR and EFS? – is there room for selecting patients who should receive (or not) adjuvant ICI (after neoadjuvant ICI and surgery)?

8 trials were included. Adjuvant ICI (perioperative) was given in 6 of them.

Alessandro Di Federico: EFS in patients with resectable NSCLC treated with neoadjuvant Chemo-IO

pCR was achieved by 22.9% of patients (ITT), while MPR by 36.1%. pCR and MPR were strongly associated with EFS, reducing the risk of an event of 87% (HR 0.13 for pCR vs non-pCR) and 82% (HR 0.18 for MPR vs non-MPR), respectively. 2Y-EFS: pCR, 94%; non-pCR, 54%; MPR, 88%; non-MPR, 48%.

Alessandro Di Federico: EFS in patients with resectable NSCLC treated with neoadjuvant Chemo-IO

Pooled EFS curves from trials that offered adjuvant ICI (perioperative) vs those that did not (neoadjuvant only) did not show significant differences regardless of achieving pCR (panel A: patients who achieved pCR; panel B: patients who did not achieve pCR).

Many Questions are yet to be answered!”

Alessandro Di Federico: EFS in patients with resectable NSCLC treated with neoadjuvant Chemo-IO

More posts featuring Alessandro Di Federico.

Dr. Alessandro Di Federico, MD, is a Medical Oncologist and PhD student at the University of Bologna and a Research Fellow at the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, Harvard University. His research focuses on identifying biomarkers to enhance personalized therapies and improve outcomes for lung cancer patients.